ESMO
Iambic's AI-Designed HER2 Drug IAM1363 Shows Durable Responses at ESMO 2026
Iambic Therapeutics has presented updated Phase 1/1b data for IAM1363, a selective, brain-penetrant HER2 tyrosine kinase inhibitor, showing durable anti-tumor activity…
NEC Bio reports 5 of 8 TNBC patients with complete response on oral neoantigen therapy
NEC Bio says five of eight patients with triple-negative breast cancer reached pathological complete response when its oral, AI-designed neoantigen therapy NECVAX-NEO1…